Furthermore, to increase the credibility of our conclusions, BC-1215, an inhibitor of FBXO3, was administered to verify that it could downregulate the levels of inflammatory cytokines caused by OGD/R in HT22 cells, coinciding with the results of Weathington et al. [41], in which BC1215 restrains NF-κB activity in acute respiratory distress syndrome (ARDS). The gene discussed is NFKB1; the disease is acute respiratory distress syndrome.